Phosphorylation of the Hippo pathway component AMOTL2 by the mTORC2 kinase promotes YAP signaling, resulting in enhanced glioblastoma growth and invasiveness

Journal of Biological Chemistry

Volumn 290, Issue 32, 2015, Pages 19387-19401

  Artinian, Nicholas ^a,c   Cloninger, Cheri ^c   Holmes, Brent ^c   Benavides Serrato, Angelica ^c   Bashir, Tariq ^a,c   Gera, Joseph ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; ANTIBIOTICS; CROSSTALK; GENE EXPRESSION; GENES; PHOSPHORYLATION; SIGNALING; TRANSCRIPTION;

INDUCED TRANSCRIPTION; PATHWAY COMPONENTS; PHARMACOLOGICAL AGENTS; REGULATORY CIRCUITS; SIGNALING CASCADES; SIGNALING PATHWAYS; TARGET OF RAPAMYCIN; THERAPEUTIC POTENTIALS;

CELL SIGNALING;

MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR YAP; UNCLASSIFIED DRUG; AMOTL2 PROTEIN, HUMAN; CARRIER PROTEIN; MULTIPROTEIN COMPLEX; PHOSPHOPROTEIN; RICTOR PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

AMOTL2 GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENE FREQUENCY; GLIOBLASTOMA; GROWTH INHIBITION; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; TUMOR INVASION; ANIMAL; BRAIN TUMOR; CANCER TRANSPLANTATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MUTATION; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR CELL LINE; XENOGRAFT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BRAIN NEOPLASMS; CARRIER PROTEINS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MICE; MICE, TRANSGENIC; MULTIPROTEIN COMPLEXES; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PHOSPHOPROTEINS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANSPLANTATION, HETEROLOGOUS;

EID: 84939233417     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M115.656587     Document Type: Article

References (46)

1. Dunn, G. P., Rinne, M. L., Wykosky, J., Genovese, G., Quayle, S. N., Dunn, I. F., Agarwalla, P. K., Chheda, M. G., Campos, B., Wang, A., Brennan, C., Ligon, K. L., Furnari, F., Cavenee, W. K., Depinho, R. A., et al. (2012) Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev. 26, 756-784
2. Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., Curschmann, J., Janzer, R. C., Ludwin, S. K., Gorlia, T., Allgeier, A., et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996
3. Masri, J., Bernath, A., Martin, J., Jo, O. D., Vartanian, R., Funk, A., and Gera, J. (2007) mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res. 67, 11712-11720
4. Tanaka, K., Babic, I., Nathanson, D., Akhavan, D., Guo, D., Gini, B., Dang, J., Zhu, S., Yang, H., De Jesus, J., Amzajerdi, A. N., Zhang, Y., Dibble, C. C., Dan, H., Rinkenbaugh, A., et al. (2011) Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discov. 1, 524-538
5. Bashir, T., Cloninger, C., Artinian, N., Anderson, L., Bernath, A., Holmes, B., Benavides-Serrato, A., Sabha, N., Nishimura, R. N., Guha, A., and Gera, J. (2012) Conditional astroglial Rictor overexpression induces malignant glioma in mice. PLoS One 7, e47741
6. Laplante, M., and Sabatini, D. M. (2012) mTOR signaling in growth control and disease. Cell 149, 274-293
7. Zoncu, R., Efeyan, A., and Sabatini, D. M. (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12, 21-35
8. Cornu, M., Albert, V., and Hall, M. N. (2013) mTOR in aging, metabolism, and cancer. Curr. Opin. Genet. Dev. 23, 53-62
9. Cybulski, N., and Hall, M. N. (2009) TOR complex 2: a signaling pathway of its own. Trends Biochem. Sci. 34, 620-627
10. Kim, S. G., Buel, G. R., and Blenis, J. (2013) Nutrient regulation of the mTOR complex 1 signaling pathway. Mol. Cells 35, 463-473
11. Sarbassov, D. D., Guertin, D. A., Ali, S. M., and Sabatini, D. M. (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101
12. Hong, W., and Guan, K. L. (2012) The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. Semin. Cell Dev. Biol. 23, 785-793
13. Mo, J. S., Park, H. W., and Guan, K. L. (2014) The Hippo signaling pathway in stem cell biology and cancer. EMBO Rep. 15, 642-656
14. Zhao, B., Li, L., Lu, Q., Wang, L. H., Liu, C. Y., Lei, Q., and Guan, K. L. (2011) Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev. 25, 51-63
15. Suzumura, A., Bhat, S., Eccleston, P. A., Lisak, R. P., and Silberberg, D. H. (1984) The isolation and long-term culture of oligodendrocytes from newborn mouse brain. Brain Res. 324, 379-383
16. Kamnasaran, D., Qian, B., Hawkins, C., Stanford, W. L., and Guha, A. (2007) GATA6 is an astrocytoma tumor suppressor gene identified by gene trapping of mouse glioma model. Proc. Natl. Acad. Sci. U.S.A. 104, 8053-8058
17. Urh, M., Simpson, D., and Zhao, K. (2009) Affinity chromatography: general methods. Methods Enzymol. 463, 417-438
18. Jo, O. D., Martin, J., Bernath, A., Masri, J., Lichtenstein, A., and Gera, J. (2008) Heterogeneous nuclear ribonucleoprotein A1 regulates cyclin D1 and c-myc internal ribosome entry site function through Akt signaling. J. Biol. Chem. 283, 23274-23287
19. Cloninger, C., Bernath, A., Bashir, T., Holmes, B., Artinian, N., Ruegg, T., Anderson, L., Masri, J., Lichtenstein, A., and Gera, J. (2011) Inhibition of SAPK2/p38 enhances sensitivity to mTORC1 inhibition by blocking IRES-mediated translation initiation in glioblastoma. Mol. Cancer Ther. 10, 2244-2256
20. Holmes, B., Artinian, N., Anderson, L., Martin, J., Masri, J., Cloninger, C., Bernath, A., Bashir, T., Benavides-Serrato, A., and Gera, J. (2012) Protor-2 interacts with tristetraprolin to regulate mRNA stability during stress. Cell. Signal. 24, 309-315
21. Hsu, P. P., Kang, S. A., Rameseder, J., Zhang, Y., Ottina, K. A., Lim, D., Peterson, T. R., Choi, Y., Gray, N. S., Yaffe, M. B., Marto, J. A., and Sabatini, D. M. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-1322
22. Mok, J., Kim, P. M., Lam, H. Y., Piccirillo, S., Zhou, X., Jeschke, G. R., Sheridan, D. L., Parker, S. A., Desai, V., Jwa, M., Cameroni, E., Niu, H., Good, M., Remenyi, A., Ma, J. L., et al. (2010) Deciphering protein kinase specificity through large-scale analysis of yeast phosphorylation site motifs. Sci. Signal. 3, ra12
23. Benavides-Serrato, A., Anderson, L., Holmes, B., Cloninger, C., Artinian, N., Bashir, T., and Gera, J. (2014) mTORC2 modulates feedback regulation of p38 MAPK activity via DUSP10/MKP5 to confer differential responses to PP242 in glioblastoma. Genes Cancer 5, 393-406
24. Chan, S. W., Lim, C. J., Chong, Y. F., Pobbati, A. V., Huang, C., and Hong, W. (2011) Hippo pathway-independent restriction of TAZ and YAP by angiomotin. J. Biol. Chem. 286, 7018-7026
25. Wang, W., Huang, J., and Chen, J. (2011) Angiomotin-like proteins associate with and negatively regulate YAP1. J. Biol. Chem. 286, 4364-4370
26. Zhao, B., Wei, X., Li, W., Udan, R. S., Yang, Q., Kim, J., Xie, J., Ikenoue, T., Yu, J., Li, L., Zheng, P., Ye, K., Chinnaiyan, A., Halder, G., Lai, Z. C., and Guan, K. L. (2007) Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 21, 2747-2761
27. Hao, Y., Chun, A., Cheung, K., Rashidi, B., and Yang, X. (2008) Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J. Biol. Chem. 283, 5496-5509
28. Liu-Chittenden, Y., Huang, B., Shim, J. S., Chen, Q., Lee, S. J., Anders, R. A., Liu, J. O., and Pan, D. (2012) Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 26, 1300-1305
29. Orr, B. A., Bai, H., Odia, Y., Jain, D., Anders, R. A., and Eberhart, C. G. (2011) Yes-associated protein 1 is widely expressed in human brain tumors and promotes glioblastoma growth. J. Neuropathol. Exp. Neurol. 70, 568-577
30. Csibi, A., and Blenis, J. (2012) Hippo-YAP and mTOR pathways collaborate to regulate organ size. Nat. Cell Biol. 14, 1244-1245
31. Paramasivam, M., Sarkeshik, A., Yates, J. R., 3rd, Fernandes, M. J., and McCollum, D. (2011) Angiomotin family proteins are novel activators of the LATS2 kinase tumor suppressor. Mol. Biol. Cell 22, 3725-3733
32. Shimobayashi, M., and Hall, M. N. (2014) Making new contacts: the mTOR network in metabolism and signalling cross-talk. Nat. Rev. Mol. Cell Biol. 15, 155-162
33. Tumaneng, K., Schlegelmilch, K., Russell, R. C., Yimlamai, D., Basnet, H., Mahadevan, N., Fitamant, J., Bardeesy, N., Camargo, F. D., and Guan, K. L. (2012) YAP mediates cross-talk between the Hippo and PI(3)K-TOR pathways by suppressing PTEN via miR-29. Nat. Cell Biol. 14, 1322-1329
34. Miller, E., Yang, J., DeRan, M., Wu, C., Su, A. I., Bonamy, G. M., Liu, J., Peters, E. C., and Wu, X. (2012) Identification of serum-derived sphingosine-1-phosphate as a small molecule regulator of YAP. Chem. Biol. 19, 955-962
35. Yu, F. X., Zhao, B., Panupinthu, N., Jewell, J. L., Lian, I., Wang, L. H., Zhao, J., Yuan, H., Tumaneng, K., Li, H., Fu, X. D., Mills, G. B., and Guan, K. L. (2012) Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 150, 780-791
36. Liang, N., Zhang, C., Dill, P., Panasyuk, G., Pion, D., Koka, V., Gallazzini, M., Olson, E. N., Lam, H., Henske, E. P., Dong, Z., Apte, U., Pallet, N., Johnson, R. L., Terzi, F., et al. (2014) Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex. J. Exp. Med. 211, 2249-2263
37. Liu, Y. C., and Wang, Y. Z. (2015) Role of Yes-associated protein 1 in gliomas: pathologic and therapeutic aspects. Tumour Biol. 36, 2223-2227
38. Fernandez-L, A., Squatrito, M., Northcott, P., Awan, A., Holland, E. C., Taylor, M. D., Nahlé, Z., and Kenney, A. M. (2012) Oncogenic YAP promotes radioresistance and genomic instability in medulloblastoma through IGF2-mediated Akt activation. Oncogene 31, 1923-1937
39. Modena, P., Lualdi, E., Facchinetti, F., Veltman, J., Reid, J. F., Minardi, S., Janssen, I., Giangaspero, F., Forni, M., Finocchiaro, G., Genitori, L., Giordano, F., Riccardi, R., Schoenmakers, E. F., Massimino, M., and Sozzi, G. (2006) Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J. Clin. Oncol. 24, 5223-5233
40. Zhang, N., Bai, H., David, K. K., Dong, J., Zheng, Y., Cai, J., Giovannini, M., Liu, P., Anders, R. A., and Pan, D. (2010) The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev. Cell 19, 27-38
41. Striedinger, K., VandenBerg, S. R., Baia, G. S., McDermott, M. W., Gutmann, D. H., and Lal, A. (2008) The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP. Neoplasia 10, 1204-1212
42. Lau, Y. K., Murray, L. B., Houshmandi, S. S., Xu, Y., Gutmann, D. H., and Yu, Q. (2008) Merlin is a potent inhibitor of glioma growth. Cancer Res. 68, 5733-5742
43. Cloughesy, T. F., Cavenee, W. K., and Mischel, P. S. (2014) Glioblastoma: from molecular pathology to targeted treatment. Annu. Rev. Pathol. 9, 1-25
44. Masui, K., Cloughesy, T. F., and Mischel, P. S. (2012) Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathol. Appl. Neurobiol. 38, 271-291
45. Grzmil, M., and Hemmings, B. A. (2013) Overcoming resistance to rapalogs in gliomas by combinatory therapies. Biochim. Biophys. Acta 1834, 1371-1380
46. Wu, S. H., Bi, J. F., Cloughesy, T., Cavenee, W. K., and Mischel, P. S. (2014) Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance. Cancer Biol. Med. 11, 255-263